Alerta

METHODS FOR TREATING INTRACRANIAL HEMORRHAGE AND ASSESSING EFFICACY

Resumen de: US20260315577A1

0000 The present disclosure relates to compositions and methods useful for assessing the hemostatic efficacy in a patient having suffered from intracranial hemorrhage while undergoing an anticoagulation treatment with a factor Xa (fXa) inhibitor. The method can include administering to the patient a fXa derivative that has reduced catalytic activity as compared to the wild-type fXa protein, is capable of binding to the factor Xa inhibitor and cannot assemble into a prothrombinase complex; obtaining a blood sample from the patient following the administration; and measuring an anti-fXa activity in the sample, wherein the anti-fXa activity reflects the hemostatic efficacy in the patient. Once the assessment is made, suitable medical interventions can be implemented.

HSP70 PROTEIN LEVELS IN PBMC SAMPLES AS BIOMARKER FOR DISEASE

Resumen de: EP4822355A2

0001 Disclosed herein are methods based on the identification of reduced Hsp70 levels in PBMC samples serving as a biomarker for diseases presenting with a reduced level of Hsp70, such as lysosomal storage diseases, neurodegenerative diseases and muscular diseases.

認知障害の処置方法

Resumen de: WO2025064229A1

The disclosure pertains to treating a cognitive impairment, for example, an aging-associated cognitive impairment. In certain aspects, the disclosure describes methods of assaying a sample obtained from a subject having or suspected of having a cognitive impairment for one or more proteins selected from: DLL1, VNN2, VAV3, and SUMF1. In certain embodiments, the cognitive impairment is caused by a neurodegenerative disease, such as Alzheimer's disease. The methods further comprise identifying a subject as likely or not likely to respond positively to the plasma exchange therapy. In even further aspects, the disclosure describes methods for treating a cognitive impairment in the subject by a plasma exchange therapy, wherein based on the specific protein expression data, the subject is identified as likely or not likely to respond positively to the plasma exchange therapy. The plasma exchange therapy can be full and/or low volume plasma exchange. Also provided are kits suitable for performing the methods disclosed herein.

항-IL-31RA 항체 및 이의 용도

Resumen de: US20250257142A1

0000 The invention provides novel anti-IL-31RA proteins, antibodies and IL-31RA binding fragments thereof, which inhibit association of IL-31 with IL-31 receptor and are suitable for administration to a human or canine subject. The invention provides novel compositions and methods of treating, alleviating the symptoms of, or preventing, allergic/inflammatory diseases, lung diseases, cardiovascular diseases, cancers, metabolic diseases, neurological diseases, and infectious diseases, comprising administering an effective amount of an anti-IL-31RA protein, antibody, or fragment thereof. The methods and compositions are used to treat or prevent IL-31-related disorders.

細胞透過剤及びその使用

Resumen de: MX2026003211A

The present disclosure provides cell-penetrating agents comprising a cell internalization module and an antibody or antigen binding antibody fragment thereof that specifically binds to human TDP-43 and methods of using these cell-penetrating agents to treat patients with TDP-43-related diseases, including Amyotrophic Lateral Sclerosis (ALS).

細胞透過剤及びその使用

Resumen de: WO2025059487A2

The present disclosure provides cell penetrating agents comprising a cell internalization module and an antibody or antigen binding antibody fragment thereof that specifically binds to human beta amyloid and methods of using these cell penetrating agents to treat patients with beta amyloid related diseases, including Inclusion-body myositis (IBM).

アミロイド疾患の診断方法

Resumen de: MX2026002775A

The present disclosure relates in some aspects to methods and compositions for detecting an amyloid-related disease in an individual.

MAGNETIC FORMULATIONS FOR BIOMARKER SAMPLING AND ENHANCED DRUG DELIVERY

Resumen de: WO2025118073A1

The present disclosure describes formulations, methods, and devices for biomarker sampling and therapeutic delivery using magnetic formulations. When combined with the application of external magnetic fields, magnetic formulations move within the nasal cavity. Magnetic formulations provide benefits including the ability to: target or steer placement of the formulations via a magnetic field, enhance mixing of the formulation via a magnetic field, enhance biological material collection via antibody-coated magnetic beads, or enhance sample retrieval via a magnetic-tipped inserter. Example biological materials for collection include proteins, enzymes, neural stem cells, and other biomarkers.

BRAIN-TARGETING PEPTIDE, TRANSPORT CARRIER, AND METHOD FOR SCREENING PEPTIDE BINDING TO TARGET CELL

Resumen de: EP4821941A1

The present invention provides a cerebrum-targeting peptide including an amino acid sequence represented by SEQ ID NO: 1, and a method for screening a peptide that binds to a target cell in a non-human organism, comprising contacting a peptide library consisting of 7-amino acid peptides with a target cell to recover a group of peptides that bind to the target cell to obtain a peptide population that binds to the target cell, and selecting, from the peptide population, a peptide consisting of an amino acid sequence that is identical to a portion of a protein expressed in the non-human organism and that is also identical to a portion of a protein constituting a virus, as a peptide that binds to the target cell.

一种检测Aβ42的光纤生物传感器及其制备方法

Resumen de: CN122901136A

0001 本发明公开了一种检测Aβ42的光纤生物传感器及其制备方法，属于光纤生物传感器技术领域，包括如下步骤：S1、采用无籽生长法制备金纳米三角片，并通过HS‑PEG‑COOH进行配体置换；S2、将单模光纤基体的待加工区域去除涂覆层后进行清洗，采用光纤熔接机对单模光纤基体进行拉锥处理，然后通过CO<2>激光周期性作用，形成TLPG传感器；S3、将TLPG传感器进行表面硅烷化修饰、金纳米三角片负载、羧基活化和抗体固定，得到光纤生物传感器；本发明利用金纳米三角片独特的尖端电场增强与微锥形长周期光纤光栅的倏逝场增强效应协同作用，实现了对Aβ42的高灵敏、快速检测。

MS4A6A抑制剂在制备治疗卵巢癌药物中的应用

Resumen de: CN122901442A

0001 本发明公开MS4A6A抑制剂在制备治疗卵巢癌药物中的应用，属于卵巢癌治疗领域；本发明提出了基于MS4A6A‑MHC‑I‑TCR轴的全新机制，通过抑制MS4A6A来下调巨噬细胞表面的MHC‑I类分子表达。避免了CD8<+>T细胞因受到持续、过度的抗原刺激而进入功能耗竭状态。结果显示，治疗后T细胞表面的耗竭标志物显著减少，效应T细胞和NK细胞在肿瘤组织的浸润密度大幅提升，成功将免疫沙漠型肿瘤转化为对免疫治疗敏感的热肿瘤。

检测抗AP2A1自身抗体的试剂在辅助诊断神经系统自身免疫性疾病中的应用、试剂盒

Resumen de: CN122901445A

0001 本发明公开了一种检测抗AP2A1自身抗体的试剂在辅助诊断神经系统自身免疫性疾病中的应用、试剂盒，属于蛋白诊断试剂制备技术领域。包括：检测抗AP2A1自身抗体的试剂在制备诊辅助断神经系统自身免疫性疾病的产品中的应用。本发明首次揭示了抗AP2A1自身抗体与神经系统自身免疫性疾病密切相关，能够区分神经系统自身免疫性疾病和其它自身免疫性疾病，尤其是区分自身免疫性脑炎和其他自身免疫性疾病，实现了神经系统自身免疫性疾病的辅助诊断，提高了诊断的准确性。

基于追踪入肝成分确定肝豆灵治疗WD肝纤维化质量标志物的方法

Resumen de: CN122901423A

本发明提出了一种基于追踪入肝成分确定肝豆灵治疗WD肝纤维化质量标志物的方法，属于中药复方活性成分鉴定技术领域。首先通过UHPLC‑Orbitrap‑MS检测肝豆灵的体外化学成分和入WD模型大鼠肝组织的原型成分，同时检测WD模型大鼠肝组织作为空白对照，依据“保留时间、峰面积差异倍数FC值>10或者模型组未检出”原则筛选入肝原型成分；然后通过网络药理学和分子对接技术，最终确定阿魏酸、芦荟大黄素、大黄酚等17个成分为肝豆灵治疗WD肝纤维化质量标志物。本发明为阐明肝豆灵治疗WD肝纤维化的药效物质基础、优化质量控制标准及新药开发提供科学的实验依据，为临床用药和新药开发提供了进一步的参考。

用于年龄预测的蛋白标志物组合及其应用

Resumen de: CN122901451A

0001 本申请涉及用于年龄预测的蛋白标志物组合及其应用。本申请还涉及检测蛋白标志物组合的试剂的用途以及用于年龄预测和衰老评估的方法，其中所述蛋白标志物组合（1）包含人血清白蛋白、凝血酶原、嗜中性粒细胞防御素1、维生素D结合蛋白、胰岛素样生长因子1、胰岛素样生长因子2、胰岛素样生长因子结合蛋白5、丝甘蛋白聚糖、前胶原C‑内肽酶增强子1和纤溶酶原；或者（2）包含人血清白蛋白的翻译后修饰，所述翻译后修饰包括人血清白蛋白的半胱氨酸氧化还原状态、甲硫氨酸氧化、赖氨酸糖化和C端完整性。本申请还涉及通过评估人血清白蛋白的翻译后修饰来识别50至60岁中年衰老转折期的方法。

一种用于诊断骨质疏松症的标志物HTRA1及其应用

Resumen de: CN122901444A

本发明属于生物医药技术领域，具体涉及一种用于诊断骨质疏松症的标志物HTRA1及其应用，其中，所述标志物为HTRA1，其在骨质疏松症患者中的表达量低。本发明通过定量检测HTRA1的水平，可以在病程早期准确识别骨质疏松症，显著提高诊断的灵敏度和特异性。这有助于医生及时采取干预措施，延缓疾病进展，减少骨折等严重并发症的发生。本发明的实施将促进对骨质疏松症分子机制的理解，HTRA1作为一种新的诊断标志物，其表达水平的变化与骨质疏松症的发病机制密切相关，在本发明公开内容的基础上有望揭示HTRA1在骨质疏松症中的角色，为疾病的治疗提供新的思路。

Hemicyanine-Based Fluorescent Probe for Peroxynitrite Detection and Its Preparation Method

Resumen de: KR20260149128A

0001a 본 발명은 과산화질산염 검출용 헤미시아닌 기반 형광 프로브 및 이의 제조 방법에 관한 것이다. 본 발명의 헤미시아닌 기반 형광 프로브는 화학식 1로 표시되는 화합물을 포함하며, 생체 내 과산화질산염(ONOO, Supattributes={}; value=-, )에 선택적으로 활성화되어 형광이 적색에서 청색 방향으로 변화하는 비율 분석 형광(ratiometric fluorophores) 특성을 나타내는 것을 특징으로 한다.

神经退行性疾病及前驱障碍的判定方法及判定装置

Resumen de: WO2025197838A1

The present invention assesses the risk of a neurodegenerative disease, and a precursor disorder for the neurodegenerative disease, using a saliva sample. An assessment device 10 comprises an inference unit 12 that inputs data of the saliva microbiome composition of a subject to each of a plurality of prediction models and obtains an inference result from each of the plurality of prediction models, and an assessment unit 13 that combines the plurality of inference results to assess the disease state of the subject. Each of the plurality of prediction models is machine-learned so as to stratify the disease state of the subject when inputting the data of the saliva microbiome composition of the subject using, as teacher data, the data of the saliva microbiome composition and the disease state of a neurodegenerative disease or a precursor disorder of the neurodegenerative disease. Each of the plurality of prediction models infers mutually different combinations of disease states.

用于半定量检测生物样本中路易折叠型α-突触核蛋白病理种子负荷的方法、试剂盒及其应用

Resumen de: CN122882748A

本发明属于生物医药技术领域，公开了一种用于半定量检测生物样本中路易折叠型α‑突触核蛋白病理种子负荷的方法、试剂盒及其应用。本发明首次将α‑突触核蛋白种子扩增技术从定性检测升级为半定量检测：首先进行阳性样本初筛，然后对初筛阳性样本进行基质匹配的系列稀释，结合长时程种子扩增反应，统计所有稀释度复孔的阳性总数，获得路易折叠病理评分。LFP评分与帕金森病患者的Hoehn&Yahr分期、MDS‑UPDRS III运动评分呈正相关，与MoCA认知评分呈负相关，可用于疾病辅助诊断、严重程度辅助评估、进展监测及药效辅助评价。该方法亦可用于检测阿尔茨海默病患者样本中的α‑突触核蛋白种子，为共病理评估提供参考。

基于PROTAC蛋白靶向降解技术的薯蓣皂素类化合物靶点鉴定方法及PROTAC化合物

Resumen de: CN122878374A

0001 本发明公开了基于PROTAC蛋白靶向降解技术的薯蓣皂素类化合物靶点鉴定方法及PROTAC化合物。本发明以薯蓣皂苷元为靶蛋白配体合成双功能PROTAC分子；通过细胞毒性筛选确定毒性最小的探针，经差异蛋白质组学分析、Western blot、分子对接及CETSA验证确证YTHDF2为作用靶标；通过AD细胞模型验证了薯蓣皂苷通过YTHDF2发挥抗氧化和缓解突突触损伤的作用机制。还提供能够诱导YTHDF2降解的薯蓣皂苷元类PROTAC化合物及其在制备治疗神经退行性疾病药物中的用途。

一种基于编码微球的弓形虫IgG抗体多指标联检方法

Resumen de: CN122882751A

本发明公开了一种基于编码微球的弓形虫IgG抗体多指标联检方法。筛选三种低吸附编码微球，分别偶联弓形虫特异性抗原SAG1、MIC3和CST1；优化偶联缓冲液为MEST pH 5.0，抗原标记量降低50%，采用1%BSA+CE210+CE510封闭。样本添加量为5μL，以TBST为清洗液，添加0.2 mg/mL阻断剂和0.01 mg/mL兔抗人IgG‑PE二抗，样本孵育与二抗孵育各15分钟即可完成检测。以健康人群检测结果的均值加3倍标准差作为阳性判断阈值，对弓形虫IgG阳性待测样本进行检测。结果显示，SAG1、MIC3、CST1三个单项抗原的阳性检出率分别为13.56%、16.95%和13.56%，而三联检的阳性检出率提升至32.20%，显著高于任一单项检测。本发明实现了快速、低成本、高灵敏度的弓形虫IgG抗体多指标联检，解决了单一抗原检出率不足的问题。

缺血性脑卒中生物标志物VTN的检测及应用

Resumen de: CN122882754A

本发明提供了缺血性脑卒中生物标志物VTN的检测及应用，属于生物医药技术领域。本发明从高通量蛋白组学筛选、生物信息学精准定位、动物模型验证、大队列临床验证形成完整证据链，系统性揭示外周来源VTN在缺血性脑卒中的诊断价值，该标志物不仅有助于全面阐释缺血性脑卒中的发病机制，还对该疾病的诊断或筛查具备高准确度，具有重要临床应用价值，为缺血性脑卒中的筛查、诊断或疗效评价提供新的技术路径和理论依据。

靶向hPVR的腺相关病毒突变体及其应用

Resumen de: CN122878457A

本发明提供工程化腺相关病毒AAV衣壳，其中所述衣壳上的至少一种蛋白质被修饰以包含一个n聚体的氨基酸序列取代或插入；用于取代或插入的氨基酸序列如序列表1中SEQ ID NOS:1‑58任一项所示。进一步的实施方案提供了一种载体系统，其包含编码AAV衣壳的一个或多个载体，以及一种向中枢神经系统递送有效载荷的方法。所述方法包括在体内或体外施用根据本文所述实施方案的AAV衣壳，且所述AAV衣壳包含一种或多种有效载荷分子。

TREATMENT OF PAIN

Resumen de: US20260306596A1

0000 The present invention is directed inter alia to the treatment of pain. For example, there is provided a chimeric clostridial neurotoxin for use in treating pain by inhibiting the release of a pain mediator from a neuron comprising an Aδ nerve fiber or a C nerve fiber, wherein the chimeric clostridial neurotoxin binds to the neuron comprising the Aδ nerve fiber or the C nerve fiber, respectively, and wherein the chimeric clostridial neurotoxin comprises a botulinum neurotoxin A (BoNT/A) light-chain and translocation domain (Hdomain), and a BoNT/B receptor binding domain (Hdomain). Also provided are methods, uses, kits, and unit dosage forms.

EARLY DETECTION AND MONITORING OF NEURODEGENERATIVE DISEASES USING A MULTIDISEASE DIAGNOSTIC PLATFORM

Resumen de: US20260309723A1

0000 Methods, systems and kits useful for the detection and diagnosis of neurodegenerative diseases including Alzheimer's Disease (AD)- and early-stage Parkinson's Disease-related pathology, and methods of preparing labeled immunocomplexes useful for detecting AD- and PD-related pathology are provided.

NOVEL LILRB2 ANTIBODIES AND USES THEREOF

Nº publicación: US20260309715A1 08/10/2026

Solicitante:

THE BOARD OF REGENTS OF THE UNIV OF TEXAS SYSTEM [US]
IMMUNE ONC THERAPEUTICS INC [US]
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
IMMUNE-ONC THERAPEUTICS, INC.

Resumen de: US20260309715A1

0000 Provided herein are antibodies binding to LILRB2 and the uses of the antibodies in detecting and treating cancer and autoimmune diseases.